Replies to post #245 on Vanda Pharmaceuticals, Inc. (VNDA)

[surf1944]

1:51AM Vanda Pharma FDA accepts Tasimelteon New Drug Application for priority review in the treatment of non-24-hour disorder in the totally blind (VNDA) 8.05 : Co announces the FDA has accepted the filing and granted a priority review classification to Vanda's New Drug Application for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.The FDA determined the action target date under Prescription Drug User Fee Act, to be January 31, 2014. The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.